Literature DB >> 6628525

On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.

K O Haustein, R G Alken, H J Lach, U Becker, N Rietbrock.   

Abstract

The pharmacokinetics of pengitoxin has been studied in 28 healthy subjects after intravenous and oral administration. The mean plasma concentration 24 h after 0.5 mg i.v. was 5.2 ng X ml-1. Following an open two-compartment model a mean elimination half-life of 60.5 h (24.9 to 103.5 h) and a mean volume of distribution (Vdarea) of 66.91 (31.8 to 109.61) were calculated. Absorption calculated by comparison of the AUC0-infinity-values amounted to 99%. Within 4 days, 16.7% (11.7 to 21.1%) or 27.8% (18.4 to 33.7%) (0.5 mg i.v. or 1.2 mg p.o.) was excreted in urine. After pengitoxin 0.5 mg i.v. total body clearance and renal clearance were 13.3 ml X min-1 (7.0 to 18.6 ml X min-1) and 3.0 ml X min-1 (1.9 to 3.9 ml X min-1) respectively. The elimination half-life of pengitoxin is longer than that of digoxin and distinctly shorter than that of digitoxin, whilst its distribution volume and clearance are closer to those of digitoxin than of digoxin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628525     DOI: 10.1007/bf01037950

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.

Authors:  J R Koup; D J Greenblatt; W J Jusko; T W Smith; J Koch-Weser
Journal:  J Pharmacokinet Biopharm       Date:  1975-06

2.  Half-life plasma following repetitive application of beta-acetyl digoxin in man.

Authors:  G G Belz; H Nübling
Journal:  Klin Wochenschr       Date:  1975-06-01

3.  Disposition of digitoxin in renal failure.

Authors:  H F Vöhringer; N Rietbrock; P Spurny; J Kuhlmann; H Hampl; R Baethke
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

4.  The estimation of non-linear parameters by internal least squares.

Authors:  H O HARTLEY
Journal:  Biometrika       Date:  1948-05       Impact factor: 2.445

5.  Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin.

Authors:  R H Reuning; R A Sams; R E Notari
Journal:  J Clin Pharmacol New Drugs       Date:  1973-04

6.  Evidence of nonlinearity in digoxin pharmacokinetics.

Authors:  J G Wagner; K D Popat; S K Das; E Sakmar; H Movahhed
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

7.  Direct radioimmunoassay for the determination of 16-acetyl-gitoxin in serum.

Authors:  E W Weiler; H J Lach
Journal:  Clin Chim Acta       Date:  1980-07-01       Impact factor: 3.786

8.  [Comparative study of the absolute bioavailability of four oral digoxin preparations (author's transl)].

Authors:  N Rietbrock; R G Alken; W Ebert
Journal:  Arzneimittelforschung       Date:  1979

9.  Pharmacokinetic investigations with 3H-penta-acetyl-gitoxin in volunteers and patients with respect to the occurrence of drug latentiation.

Authors:  K O Haustein; C Pachaly; D Murawski
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-06

10.  Measurement of plasma glycoside level following pengitoxin administration.

Authors:  K O Haustein
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

View more
  2 in total

Review 1.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

2.  On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.

Authors:  K O Haustein
Journal:  J Pharmacokinet Biopharm       Date:  1986-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.